Understanding the impact of pandemics on long-term medication adherence: directly observed therapy in a tuberculosis treatment cohort pre- and post-COVID-19 lockdowns

BMC Infect Dis. 2024 Oct 14;24(1):1154. doi: 10.1186/s12879-024-09994-7.

Abstract

Background: The COVID-19 pandemic negatively impacted tuberculosis (TB) treatment services, including directly observed therapy (DOT) programs used to promote medication adherence. We compared DOT adherence embedded in a research study before and after COVID-19 lockdowns in South Africa.

Methods: We analyzed data from 263 observational study participants undergoing drug susceptible (DS)-TB DOT between May 2017 to March 2022. Participants enrolled before October 2019 were considered 'pre-COVID-19' and those enrolled after September 2020 were considered 'post-COVID-19 lockdown groups. Negative binomial regression models were used to compare DOT non-adherence rates between the two lockdown groups. We then conducted a sensitivity analysis which only included participants enrolled in the immediate period following the first COVID-19 lockdown.

Results: DOT non-adherence rate was higher in the post-COVID-19 lockdown group (aIRR = 1.42, 95% CI = 1.04-1.96; p = 0.028) compared to pre-COVID-19 lockdown period, adjusting for age, sex, employment status, household hunger, depression risk, and smoked substance use. DOT non-adherence was highest immediately following the initial lockdown (aIRR = 1.74, 95% CI = 1.17-2.67; p = 0.006).

Conclusion: The COVID-19 lockdowns adversely effected adherence to TB DOT in the period after lockdowns were lifted. The change in DOT adherence persisted even after adjusting for socioeconomic and behavioral variables. We need a better understanding of what treatment adherence barriers were exacerbated by COVID-19 lockdowns to improve outcomes in post-pandemic times.

Trial registration: ClinicalTrials.gov Registration Number: NCT02840877. Registered on 19 July 2016.

Keywords: Mycobacterium tuberculosis; Adherence; Drug-susceptible TB; SARS-CoV-2; South Africa.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Antitubercular Agents* / administration & dosage
  • Antitubercular Agents* / therapeutic use
  • COVID-19* / epidemiology
  • Cohort Studies
  • Directly Observed Therapy*
  • Female
  • Humans
  • Male
  • Medication Adherence* / statistics & numerical data
  • Middle Aged
  • Pandemics
  • SARS-CoV-2
  • South Africa / epidemiology
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology

Substances

  • Antitubercular Agents

Associated data

  • ClinicalTrials.gov/NCT02840877